You just read:

Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability

News provided by

Chimerix, Inc.

Dec 13, 2010, 08:30 ET